Tirzepatide vs. Semaglutide: What the Head-to-Head Evidence Says
Two weekly injections dominate the conversation about diabetes and obesity treatment. When they are compared directly, one tends to come out ahead on weight and blood sugar — but the fuller picture is more nuanced.
By Wellness Wire Editorial
Tirzepatide and semaglutide are the two medicines behind the recent surge of interest in injectable treatments for type 2 diabetes and obesity. Both are given as a weekly shot, both lower blood sugar and body weight, and both have been studied in large trials. Because they are so often mentioned in the same breath, a natural question follows: when the two are compared directly, which one comes out ahead, and how confident can we be? Here is what the head-to-head evidence actually shows, and where it runs out.
Two drugs, one shared root, and one key difference
The two drugs share a family resemblance but are not identical. Semaglutide is a selective GLP-1 receptor agonist: it mimics a single gut hormone, GLP-1, that helps regulate appetite and blood sugar. Tirzepatide acts on two receptors at once. It is a dual GIP and GLP-1 receptor agonist, and it is the first and, at the time of these studies, only such drug approved by the U.S. Food and Drug Administration. It is sold as Mounjaro for diabetes and Zepbound for obesity.
That second target may matter. Laboratory work describes tirzepatide as an "imbalanced" and "biased" agonist: it is roughly as potent as the body's own GIP at the GIP receptor, but binds the GLP-1 receptor about five times more weakly than native GLP-1. Researchers think the added GIP activity is part of what strengthens its metabolic effect. Whether that mechanism fully explains the differences seen in patients is not something a lab study alone can prove.
The diabetes head-to-head: SURPASS-2
The clearest direct comparison in type 2 diabetes is SURPASS-2. Over 40 weeks, 1,879 adults already taking metformin were randomly assigned to one of three tirzepatide doses (5, 10 or 15 mg) or to injectable semaglutide at 1 mg. All three tirzepatide doses were superior to semaglutide on both blood-sugar control and weight.
- HbA1c, a measure of average blood sugar, fell about 2.09%, 2.37% and 2.46% on tirzepatide 5, 10 and 15 mg, versus 1.86% on semaglutide 1 mg.
- Body weight fell about 7.8, 10.3 and 12.4 kg across the three tirzepatide doses, versus 6.2 kg on semaglutide 1 mg.
One caveat is essential to reading this trial fairly: it used the 1 mg diabetes dose of semaglutide, not the higher 2.4 mg dose approved for weight loss. So SURPASS-2 is a fair test in diabetes, but it is not the fair test for weight loss.
The weight-loss head-to-head: SURMOUNT-5
For weight loss, the comparison that matters is SURMOUNT-5. It enrolled 751 adults who had obesity but not diabetes and followed them for 72 weeks, comparing the two drugs at their maximum tolerated doses, the matchup the diabetes trial could not provide. Tirzepatide again came out ahead.
- Average weight change was -20.2% with tirzepatide versus -13.7% with semaglutide.
- Waist circumference fell 18.4 cm with tirzepatide versus 13.0 cm with semaglutide.
- Both differences were statistically significant (p<0.001).
Each drug also has strong standalone evidence. In SURMOUNT-1, tirzepatide produced mean weight reductions of 16.0%, 21.4% and 22.5% (5, 10 and 15 mg) versus 2.4% for placebo over 72 weeks, with 89 to 96% of treated participants losing at least 5% of their body weight versus 28% on placebo. In STEP 1, semaglutide 2.4 mg produced a mean change of -14.9% versus -2.4% with placebo over 68 weeks, with 86.4% losing at least 5% versus 31.5%. It is tempting to line those two headline numbers up side by side, but that is not a valid comparison: the trials enrolled different people, ran for different lengths, and used different lifestyle programs. SURMOUNT-5 is the comparison to trust.
In both direct comparisons, diabetes and weight loss, tirzepatide outperformed semaglutide. But "better on average" is not the whole story.
Hearts, sleep, and what we don't know
Weight and blood sugar are not the only outcomes that matter, and here the picture shifts. Semaglutide has the more mature evidence for preventing cardiovascular events. In SELECT, which followed 17,604 adults who had cardiovascular disease and overweight or obesity but not diabetes, semaglutide 2.4 mg reduced major adverse cardiovascular events to 6.5% from 8.0% (hazard ratio 0.80; 95% CI 0.72-0.90; p<0.001), a 20% relative reduction, over a mean follow-up of about 40 months.
Tirzepatide's dedicated cardiovascular trial, SURPASS-CVOT, tells a more limited story so far. In 13,165 adults with type 2 diabetes and atherosclerotic disease followed for a median of about four years, tirzepatide was tested against an active comparator, the GLP-1 drug dulaglutide, not against placebo and not against semaglutide. It met the bar for non-inferiority (hazard ratio 0.92, roughly 12% versus 13% of participants having an event) but did not establish superiority (p=0.09). Crucially, no trial has ever pitted tirzepatide directly against semaglutide for cardiovascular outcomes, so any comparison on the heart is indirect.
Tirzepatide has also been studied in obstructive sleep apnea. In SURMOUNT-OSA, adults with moderate-to-severe sleep apnea and obesity saw large drops in the apnea-hypopnea index versus placebo, on the order of 25 to 30 fewer breathing events per hour, and up to about 43% (not using a breathing machine) to 51.5% (using one) met criteria for disease resolution. That trial had no semaglutide arm, so it speaks to tirzepatide's own effects, not to a comparison between the two drugs.
How to read this evidence
A few limitations shape how much weight to place on all of this.
- Both head-to-head trials (SURPASS-2 and SURMOUNT-5) were open-label, meaning patients and staff knew which drug was given, which can influence subjective outcomes and behavior. The placebo-controlled trials (SURMOUNT-1, STEP 1 and SELECT) were double-blind.
- Reported percentages depend on how the data are analyzed. Manufacturer press releases tend to cite the more favorable "efficacy estimand," which assumes full adherence, so figures can differ slightly from other reported numbers for the same trial.
- The cardiovascular comparison is indirectsemaglutide has shown event reduction versus placebo, while tirzepatide has shown only non-inferiority to another active drug.
- This field and its labeling change quickly. Approved uses, dosing and safety information, including boxed warnings such as the risk of thyroid C-cell tumors seen in rodents, should be checked against current FDA prescribing information.
- 01 Eli Lilly / PR Newswire (SURPASS-2, published in NEJM), 2021 prnewswire.com ↗Head-to-head diabetes trial press release; HbA1c and weight figures for tirzepatide vs semaglutide 1 mg.
- 02 Society summary of the direct weight-loss head-to-head; -20.2% vs -13.7% weight and waist figures.
- 03 Eli Lilly / PR Newswire (SURMOUNT-1, published in NEJM), 2022 prnewswire.com ↗Tirzepatide standalone obesity results and description as a dual GIP/GLP-1 agonist.
- 04 Society summary of semaglutide 2.4 mg vs placebo for obesity; -14.9% weight change.
- 05 American College of Cardiology clinical trial summary (SELECT, Lincoff et al., NEJM), 2023 acc.org ↗Semaglutide cardiovascular-outcomes trial; MACE 6.5% vs 8.0%, HR 0.80.
- 06 JCI Insight (Willard et al.), 2020 insight.jci.org ↗Mechanistic study describing tirzepatide as an imbalanced, biased dual GIP and GLP-1 receptor agonist; ~5-fold weaker GLP-1R affinity than native GLP-1, equipotent to native GIP.
- 07 Tirzepatide vs placebo in obstructive sleep apnea; apnea-hypopnea index and disease-resolution figures (43.0% non-PAP, 51.5% on PAP).
- 08 Tirzepatide vs dulaglutide cardiovascular-outcomes trial; non-inferiority (HR 0.92) without superiority (p=0.09).
Wellness Wire Editorial
The Wellness Wire editorial team. Our explainers are researched from primary sources — clinical-trial reports and FDA labeling — and written for general education. They are not individually reviewed by a clinician and are not a substitute for medical advice.
